I 3 PHARMS
GenericsI 3 PHARMS is a generic drug manufacturer focused on Immunology, Infectious Disease, Cardiovascular.
Upcoming FDA Decisions
Full Calendar →I 3 PHARMS's Key Drugs
I 3 PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
I 3 PHARMS's Recent FDA Approvals
New NDA/BLA approvals for I 3 PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
I 3 PHARMS's Therapeutic Areas
I 3 PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
I 3 PHARMS's Top Competitors
I 3 PHARMS's closest competitors by therapeutic-area and drug-target overlap include Sanofi, BAUSCH AND LOMB INC, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
I 3 PHARMS Pipeline Snapshot
Active clinical trials for I 3 PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-08-17
- Latest
- 2026-01-26
- Applications
- 4